Food supplement

Abstract

A food supplement is composed of a water-insoluble extract of a microalga and at least one oil selected from medium-chain triglycerides (MCT), wherein the extract of microalga comprises at least 25 mg/g of one or several omega-3 type fatty acid(s), at least 5 mg/g of one or several xanthophyll(s), at least 0.5 mg/g of one or several sterol(s) and at least 1 μg/g of one or several phycoprostane(s). A method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions, or cognitive disorders in children or young adults having been subjected to a prenatal stress inducing non-pathological disorders, such as hyperactivity, attention and memory deficit, language retardation and anxious behavior, involves administration of an effective amount of the food supplement to a human in need thereof.

1 . A food supplement comprising a water-insoluble extract of a microalga and at least one oil selected from medium-chain triglycerides (MCT), wherein the extract of microalga comprises at least 25 mg/g of one or several omega-3 type fatty acid(s), at least 5 mg/g of one or several xanthophyll(s), at least 0.5 mg/g of one or several sterol(s) and at least 1 μg/g of one or several phycoprostane(s). 
     
     
         2 . The food supplement according to  claim 1 , wherein the extract comprises 25 to 250 mg/g of one or several omega-3 type fatty acid(s), 5 to 50 mg/g of one or several xanthophyll(s), 0.5 to 20 mg/g of one or several sterol(s), 1 to 100 μg/g of one or several phycoprostane(s). 
     
     
         3 . The food supplement according to  claim 1 , wherein the extract comprises 25 to 200 mg/g of one or several omega-3 type fatty acid(s), 5 to 30 mg/g of one or several xanthophyll(s), 0.5 to 8 mg/g of one or several sterol(s) and 1 to 50 μg/g of one or several phycoprostane(s). 
     
     
         4 . The food supplement according to  claim 1 , wherein the extract comprises 25 to 170 mg/g of one or several omega-3 type fatty acid(s), 5 to 25 mg/g of one or several xanthophyll(s), 0.5 to 6 mg/g of one or several sterol(s) and 1 to 40 μg/g of one or several phycoprostane(s). 
     
     
         5 . The food supplement according to  claim 1 , wherein the medium-chain triglycerides (MCT) are selected from coconut palm oil and palm oil. 
     
     
         6 . The food supplement according to  claim 1 , wherein the or at least one of the omega-3 type fatty acids is selected from ALA (α-linolenic acid), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and mixtures thereof. 
     
     
         7 . The food supplement according to  claim 1 , wherein the at least one of the xanthophylls is fucoxanthin. 
     
     
         8 . The food supplement according to  claim 1 , wherein the or at least one of the sterols is selected from phytosterols. 
     
     
         9 . The food supplement according to  claim 1 , wherein the or at least one of the phycoprostanes is selected from phytoprostanes, isoprostanes and neuroprostanes. 
     
     
         10 . The food supplement according to  claim 1 , which further comprises at least one additive selected from preservative agents, colorants, flavors, disintegration agents, lubricant agents, coating or encapsulation agents. 
     
     
         11 . The food supplement according to  claim 1 , which is in the form of gel capsules, capsules, tablets, pastilles or loose powder. 
     
     
         12 . The food supplement according to  claim 1 , which is packaged in doses having a unit weight comprised between 10 mg and 1 g. 
     
     
         13 . The food supplement according to  claim 1 , wherein the microalga is selected from any one of the taxons Pinguiophyceae, Chrysophyceae, Bacillariophyceae, Mamiellophyceae, Prymnesiophyceae, Haptophyceae, Coccolithophyceae, lsochrysidaceae and Phaeodactylaceae. 
     
     
         14 . The food supplement according to  claim 13 , wherein said microalga is  Tisochrysis lutea  or  Phaeodactylum tricornutum.    
     
     
         15 . A method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions, or cognitive disorders in children or young adults having been subjected to a prenatal stress inducing non-pathological disorders, such as hyperactivity, attention and memory deficit, language retardation and anxious behavior, comprising the administration of an effective amount of a food supplement according to  claim 1  to a human in need thereof. 
     
     
         16 . The method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions according to  claim 15 , wherein the age-related cognitive disorders are chosen from deficit in spatial working memory, deficit in attention and vigilance, deficit in executive function, deficit in episodic memory, and deficit in perceptual and cognitive skills. 
     
     
         17 . The method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions according to  claim 16 , in order to improve calmness and reduce perceived stress. 
     
     
         18 . The method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions according to  claim 15  comprising the administration of an effective amount of a food supplement according to  claim 1  to a healthy older human aged between 55 and 75 years old. 
     
     
         19 . The method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions according to  claim 15 , wherein the effective amount corresponds to a daily intake of between 2 to 16 mg of food supplement/kg of body weight. 
     
     
         20 . The method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions according to  claim 19 , wherein the food supplement is orally administrated during between 1 month to 6 months. 
     
     
         21 . The method for preventing the apparition of cognitive disorders in children or young adults having been subjected to a prenatal stress inducing non-pathological disorders, such as hyperactivity, attention and memory deficit, language retardation and anxious behavior according to  claim 15 , wherein the effective amount corresponds to a daily intake of between 0.05 to 0.1 mg of food supplement/kg of body weight.